The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human
Abstract
INTRODUCTION: HepaRG is a unique cell line showing a great plasticity, which differentiates to both canaliculae-like and hepatocyte-like cells. The long-term stability of key cell functions, for example, the drug-metabolizing cytochrome P450 (CYP) enzyme activities, in culture is especially useful in drug metabolism, disposition and toxicity studies. AREAS COVERED: This review describes features of the HepaRG cells focusing on drug-metabolizing enzymes and drug transporters, their functionality and regulation. Several applications in drug discovery studies are discussed and the use of HepaRG, as a human relevant predictive in vitro CYP induction model, is described. In addition, promising studies using HepaRG cells for understanding liver toxicity mechanisms by drug compounds are also discussed. EXPERT OPINION: HepaRG cells exhibit features which make them useful as an in vitro model for drug metabolism, disposition and toxicity studies, and could, for many studies, replace the requirement for primary human hepatocytes. Care should be taken since HepaRG cells are of a specific genotype which is reflected in the expression of drug processing proteins. The finding that HepaRG cells form tight junctions provides the basis for formation of functional canalicular structures and this should be investigated further to aid development of human relevant hepatic in vitro 2D and 3D models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Infection of a human hepatoma cell line by hepatitis B virus
Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., & Guguen-Guillouzo, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232137699 · Cited by 1,282
Aninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langouët, S., Morel, F., Guguen-Guillouzo, C., & Guillouzo, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006759 · Cited by 703
Gerets, H. H. J., Tilmant, K., Gerin, B., Chanteux, H., Depelchin, B. O., Dhalluin, S., & Atienzar, F. A. (2012) · Cell Biology and Toxicology · doi:10.1007/s10565-011-9208-4 · Cited by 698
Managing the challenge of chemically reactive metabolites in drug development
Park, B. K., Boobis, A., Clarke, S., Goldring, C. E. P., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 462
Self-citationCerec, V., Glaise, D., Garnier, D., Morosan, S., Turlin, B., Drenou, B., Gripon, P., Kremsdorf, D., Guguen‐Guillouzo, C., & Corlu, A. (2007) · Hepatology · doi:10.1002/hep.21536 · Cited by 371
Swift*, B., Pfeifer*, N. D., & Brouwer, K. L. R. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491881 · Cited by 365
Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies
Kanebratt, K. P., & Andersson, T. B. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.020016 · Cited by 354
Self-citationGuo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.-L., Green, B., Deng, H., Kaput, J., & Ning, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035873 · Cited by 348
Hart, S. N., Li, Y., Nakamoto, K., Subileau, E.-A., Steen, D., & Zhong, X.-B. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031831 · Cited by 296
HepaRG Cells: A Human Model to Study Mechanisms of Acetaminophen Hepatotoxicity Δσ
McGill, M. R., Yan, H.-M., Ramachandran, A., Murray, G. J., Rollins, D. E., & Jaeschke, H. (2011) · Hepatology · doi:10.1002/hep.24132 · Cited by 294
Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells
Anthérieu, S., Chesné, C., Li, R., Camus, S., Lahoz, A., Picazo, L., Turpeinen, M., Tolonen, A., Uusitalo, J., Guguen-Guillouzo, C., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030197 · Cited by 278
Origin and characterization of a human bipotent liver progenitor cell line☆
Parent, R., Marion, M.-J., Furio, L., Trépo, C., & Petit, M.-A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.002 · Cited by 241
HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans
Kanebratt, K. P., & Andersson, T. B. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017418 · Cited by 214
Self-citationLe Vee, M., Jigorel, E., Glaise, D., Gripon, P., Guguen-Guillouzo, C., & Fardel, O. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.004 · Cited by 190
Jossé, R., Aninat, C., Glaise, D., Dumont, J., Fessard, V., Morel, F., Poul, J.-M., Guguen-Guillouzo, C., & Guillouzo, A. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019901 · Cited by 187
Anthérieu, S., Rogue, A., Fromenty, B., Guillouzo, A., & Robin, M.-A. (2011) · Hepatology · doi:10.1002/hep.24290 · Cited by 167
Vée, M. L., Gripon, P., Stieger, B., & Fardel, O. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016907 · Cited by 150
Hepatocyte Polarization Is Essential for the Productive Entry of the Hepatitis B Virus
Schulze, A., Mills, K., Weiß, T. S., & Urban, S. (2011) · Hepatology · doi:10.1002/hep.24707 · Cited by 150
Bazin, E., Mourot, A., Humpage, A. R., & Fessard, V. (2009) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20539 · Cited by 135
Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
Rogue, A., Lambert, C. B., Jossé, R., Anthérieu, S., Spire, C., Claude, N., & Guillouzo, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018816 · Cited by 119
Zeilinger, K., Schreiter, T., Darnell, M., Söderdahl, T., Lübberstedt, M., Dillnér, B., Knobeloch, D., Nussler, A. K., Gerlach, J. C., & Andersson, T. B. (2011) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2010.0580 · Cited by 118
Self-citationFunctional expression, inhibition and induction of CYP enzymes in HepaRG cells
Turpeinen, M., Tolonen, A., Chesné, C., Guillouzo, A., Uusitalo, J., & Pelkonen, O. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.03.008 · Cited by 117
Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines
Fardel, O., & Vée, M. L. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903304056 · Cited by 97
McGinnity, D. F., Zhang, G., Kenny, J. R., Hamilton, G. A., Otmani, S., Stams, K. R., Haney, S., Brassil, P. J., Stresser, D. M., & Riley, R. J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026526 · Cited by 90
Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes
Petit, E., Langouët, S., Akhdar, H., Nicolaz, C. N., Guillouzo, A., & Morel, F. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.12.004 · Cited by 78
The HepaRG cell line is suitable for bioartificial liver application
Hoekstra, R., Nibourg, G. A. A., van der Hoeven, T. V., Ackermans, M. T., Hakvoort, T. B. M., van Gulik, T. M., Lamers, W. H., Elferink, R. P. J. O., & Chamuleau, R. A. F. M. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.06.011 · Cited by 78
Zanelli, U., Caradonna, N. P., Hallifax, D., Turlizzi, E., & Houston, J. B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042309 · Cited by 76
Legendre, C., Hori, T., Loyer, P., Aninat, C., Ishida, S., Glaise, D., Lucas‐Clerc, C., Boudjéma, K., Guguen‐Guillouzo, C., Corlu, A., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.07.010 · Cited by 75
Darnell, M., Schreiter, T., Zeilinger, K., Urbaniak, T., Söderdahl, T., Rossberg, I., Dillnér, B., Berg, A., Gerlach, J. C., & Andersson, T. B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037721 · Cited by 75
Self-citationHégarat, L. L., Dumont, J., Jossé, R., Huet, S., Lanceleur, R., Mourot, A., Poul, J.-M., Guguen‐Guillouzo, C., Guillouzo, A., & Fessard, V. (2010) · Mutagenesis · doi:10.1093/mutage/geq039 · Cited by 74
Rogue, A., Lambert, C. B., Spire, C., Claude, N., & Guillouzo, A. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042028 · Cited by 72
Pernelle, K., Guével, R. L., Glaise, D., Gaucher, C., Charpentier, T. L., Bouaita, B., Corlu, A., & Guguen‐Guillouzo, C. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.04.018 · Cited by 66
Jossé, R., Dumont, J., Fautrel, A., Robin, M., & Guillouzo, A. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.10.019 · Cited by 65
Regulation of drug transporter expression by oncostatin M in human hepatocytes
Vée, M. L., Jouan, E., Stieger, B., Lecureur, V., & Fardel, O. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.04.017 · Cited by 39
Vée, M. L., Jouan, E., & Fardel, O. (2010) · Toxicology in Vitro · doi:10.1016/j.tiv.2010.07.001 · Cited by 33
Elliott, N. T., & Yuan, F. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.24397 · Cited by 33
Madec, S., Cérec, V., Plée‐Gautier, E., Antoun, J., Glaise, D., Salaün, J., Guguen‐Guillouzo, C., & Corlu, A. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036848 · Cited by 29
CYP4A11 is repressed by retinoic acid in human liver cells
Antoun, J., Amet, Y., Simon, B., Dréano, Y., Corlu, A., Corcos, L., Salaun, J. P., & Plée‐Gautier, E. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.05.006 · Cited by 26
Prediction of clinical CYP3A4 induction using cryopreserved human hepatocytes
Kaneko, A., Kato, M., Endo, C., Nakano, K., Ishigai, M., & Takeda, K. (2010) · Xenobiotica · doi:10.3109/00498254.2010.517277 · Cited by 13
Cited by
Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids
Mun, S. J., Ryu, J.-S., Lee, M.-O., Son, Y. S., Oh, S. J., Cho, H.-S., Son, M.-Y., Kim, D.-S., Kim, S. J., Yoo, H. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.030 · Cited by 373
Bauer, S., Wennberg Huldt, C., Kanebratt, K. P., Durieux, I., Gunne, D., Andersson, S., Ewart, L., Haynes, W. G., Maschmeyer, I., Winter, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14815-w · Cited by 272
Self-citationCell sources for in vitro human liver cell culture models
Zeilinger, K., Freyer, N., Damm, G., Seehofer, D., & Knöspel, F. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216657448 · Cited by 230
“HepaRG cells show a high grade of differentiation and expression of typical hepatic functions, including CYP-dependent metabolism, CYP induction, and drug transporter expression.(72) Evaluation Figure 3 Miniaturized four-compartment bioreactor for high-density perfusion culture of liver cells.”
BackgroundIn Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121
Human in vitro models of nonalcoholic fatty liver disease
Müller, F. A., & Sturla, S. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.03.001 · Cited by 118
Metadata
- Authors
- Andersson, T. B., Kanebratt, K. P., & Kenna, J. G.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2012-05-08
- Volume
- 8
- Issue
- 7
- Pages
- 909-920
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2136693019
- Cited by
- 259
- References
- 41
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.